Skip to main content
SpringerLink
Log in

Therapie entzündlicher Nierenerkrankungen

Mehr als Steroide?

Therapy of inflammatory kidney diseases—more than steroids?

  • Schwerpunkt: Was ist gesichert in der Therapie?
  • Published:
Der Internist Aims and scope Submit manuscript

An Erratum to this article was published on 01 February 2005

Zusammenfassung

Der Begriff „entzündliche Nierenerkrankung“, so wie er in dieser Übersicht verwendet wird, klassifiziert eine immunpathogenetisch bedingte, beide Nieren befallende Erkrankung. Bakterielle Infektionen und interstitielle Nephritiden werden hier nicht dargestellt. Die Einteilung und Terminologie entzündlicher Nierenerkrankungen erfolgt v. a. nach morphologischen Kriterien, nach der Akutizität des Krankheitsverlaufs und nach der weiteren Organbeteiligung. Von einer primären Form spricht man, wenn die Nierenerkrankung ohne, von einer sekundären Form, wenn sie mit einer Systemerkrankung einhergeht. Umfassende Übersichten dazu unter Einbeziehung des klinischen Verlaufs und der Symptomatik wurden im Internisten 1997 und 2002 publiziert.

Abstract

The term “inflammatory kidney diseases” characterizes primarily immunopathogenetically driven diseases, affecting both kidneys. Bacterial infections, or primarily interstitial nephritis, shall not be considered in this overview. Classification and terminology of inflammatory kidney diseases follow morphological criteria, acuteness of the clinical course, and concomitant organ affection. The clinical course and pathology of inflammatory kidney diseases have been reviewed extensively in this journal in 1997 and 2002.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42: 1114–1120

    Article  CAS  PubMed  Google Scholar 

  2. Birck R, Warnatz K, Lorenz HM et al. (2003) 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 14: 440–447

    CAS  PubMed  Google Scholar 

  3. Booth A, Harper L, Hammad T et al. (2004) Prospective study of TNF{alpha} blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15: 717–721

    CAS  PubMed  Google Scholar 

  4. Chan TM, Li FK, Tang CS et al. (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343: 1156–1162

    Article  CAS  PubMed  Google Scholar 

  5. Couser WG (1988) Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 11: 449–464

    CAS  PubMed  Google Scholar 

  6. Donadio JV, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC (1999) The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 10: 1772–1777

    CAS  PubMed  Google Scholar 

  7. de Groot K, Adu D, Savage CO (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16: 2018–2027

    Article  PubMed  Google Scholar 

  8. du Buf-Vereijken PWG, Wetzels JFM (2004) Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol Dial Transplant 19: 2036–2043

    Article  PubMed  Google Scholar 

  9. Edwards JCW, Szczepanski L, Szechinski J et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572–2581

    Article  CAS  PubMed  Google Scholar 

  10. Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 76–85

    CAS  PubMed  Google Scholar 

  11. Floege J (2003) Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrol Dial Transplant 18: 241–245

    Article  CAS  PubMed  Google Scholar 

  12. Grabensee B, Bach D, Heering P (2004) Immunsuppression in der Therapie der Glomerulonephritis. Internist (Berl) 38: 562–573

  13. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS, Rovin BH (2001) Renoprotection: one or many therapies? Kidney Int 59: 1211–1226

    Article  CAS  PubMed  Google Scholar 

  14. Jayne D, Rasmussen N, Andrassy K et al., the European Vasculitis Study Group (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36

    Article  CAS  PubMed  Google Scholar 

  15. Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, Van der Woude FJ (1999) Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10: 1965–1971

    CAS  PubMed  Google Scholar 

  16. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M (2003) Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14: 1851–1859

    CAS  PubMed  Google Scholar 

  17. Schmidt U, Franke J, Thomae U, Mann J (2002) Glomerulonephritis. Internist (Berl) 43: 749–756

    Google Scholar 

  18. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ (2004) Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): An open study in 15 patients. Kidney Int 65: 1440–1448

    Article  CAS  PubMed  Google Scholar 

  19. Specks U, Fervenza FC, McDonald TJ, Hogan MC (2001) Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44: 2836–2840

    Article  CAS  PubMed  Google Scholar 

  20. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS (2001) Etanercept combined with conventional treatment in Wegener’s granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 44: 1149–1154

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Abteilung für Nephrologie, Medizinische Klinik, Universitätsklinikum Würzburg

    J. Galle & S. Seibold

  2. Abteilung für Nephrologie, Medizinische Klinik, Universitätsklinikum, Josef-Schneider-Straße 2, 97080, Würzburg

    J. Galle

Authors
  1. J. Galle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Seibold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Galle.

Additional information

Ein Erratum zu diesem Beitrag ist unter http://dx.doi.org/10.1007/s00108-005-1363-3 zu finden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galle, J., Seibold, S. Therapie entzündlicher Nierenerkrankungen. Internist 45, 1388–1394 (2004). https://doi.org/10.1007/s00108-004-1298-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-004-1298-0

Schlüsselwörter

Keywords

Search

Navigation